Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press35310.17650/1726-9776-2012-8-4-33-39DIAGNOSIS AND TREATMENT OF URINARY SYSTEM TUMORS. URINARY BLADDER CANCERДИАГНОСТИКА И ЛЕЧЕНИЕ ОПУХОЛЕЙ МОЧЕПОЛОВОЙ СИСТЕМЫ. Рак мочевого пузыряIMPACT OF REPEAT TRANSURETHRAL RESECTION ON TREATMENT RESULTS IN PATIENTS WITH NON-MUSCLE-INVASIVE BLADDER CANCERВЛИЯНИЕ ПОВТОРНОЙ ТРАНСУРЕТРАЛЬНОЙ РЕЗЕКЦИИ НА РЕЗУЛЬТАТЫ ЛЕЧЕНИЯ БОЛЬНЫХ НЕМЫШЕЧНО-ИНВАЗИВНЫМ РАКОМ МОЧЕВОГО ПУЗЫРЯKhalmurzayevO. A.ХалмурзаевО. А.
Russian Federation
oybekkhalmurzaev@mail.ruMatveevV. B.МатвеевВ. Б.
Russian Federation
oybekkhalmurzaev@mail.ruFigurinR. M.ФигуринК. М.
Russian Federation
oybekkhalmurzaev@mail.ruRomanovV. A.РомановВ. А.
Russian Federation
oybekkhalmurzaev@mail.ruPanakhovA. D.ПанаховА. Д.
Russian Federation
oybekkhalmurzaev@mail.ruKhafizovK. O.ХафизовК. О.
Russian Federation
oybekkhalmurzaev@mail.ruDepartment of Urology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, MoscowОтделение урологии ФГБУ «РОНЦ им. Н.Н. Блохина» РАМН, Москва301220128433390708201407082014https://oncourology.abvpress.ru/oncur/article/view/353

The results of treatment were analyzed in 308 in patients with non-muscle-invasive (NMI) bladder cancer (BC). The incidence of recurrences was studied in patients with NMI BC who had undergone primary and second look (SL) transurethral resection (TUR). SL TUR is used to identify residual Т1G2−G3 tumors and to specify the stage of the disease, owing to which treatment policy for BC is changed. The authors revealed significant differences between the groups in the rate of early and recurrent NMI BC and its occurrence time during 5 years. The findings show the benefit of relapse-free survival after SL TUR in the T1G2-G3 BC group (p = 0.018). The authors also discuss whether it is reasonable to use SL TUR that allows this procedure to be recommended for patients with G2-G3 NMI BC in routine clinical practice.

Проанализированы результаты лечения 308 пациентов с немышечно-инвазивным (НМИ) раком мочевого пузыря (РМП). Изучена частота встречаемости рецидивов у пациентов с НМИ РМП с однократной и повторной (second look – SL) трансуретральной резекцией (ТУР). Посредством SL ТУР выявляются резидуальные опухоли Т1G2−G3, уточняется стадия заболевания, благодаря чему изменяется тактика лечения РМП. Нами выявлены достоверные различия между группами в частоте и сроках возникновения ранних и рецидивов в течение 5 лет. Полученные результаты отражают преимущество безрецидивной выживаемости после выполнения SL ТУР в группах больных РМП T1G2–3 (р = 0,018). Также обсуждается целесообразность применения SL ТУР, позволяющая рекомендовать эту методику пациентам с НМИ РМП G2−3 для рутинной клинической практики.

non-muscle-invasive bladder cancertransurethral resection of the bladdersecond lookincidence of recurrencesrestagingнемышечно-инвазивный рак мочевого пузырятрансуретральная резекция мочевого пузыряsecond lookчастота встречаемости рецидивоврестадирование1. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2010.Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В. Старинского, Г.В. Петровой. М., 2010.2. Матвеев Б.П. Клиническая онкоурология. М., 2011.Матвеев Б.П. Клиническая онкоурология. М., 2011.3. Dominguez G., Carballido J., Silva J. et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 2002;8:980−5.Dominguez G., Carballido J., Silva J. et al. p14ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 2002;8:980−5.4. Русаков И.Г., Быстров А.А. Хирургическое лечение, химио- и иммунотерапии больных поверхностным раком мочевого пузыря. Практ онкол 2003;1:107−16.Русаков И.Г., Быстров А.А. Хирургическое лечение, химио- и иммунотерапии больных поверхностным раком мочевого пузыря. Практ онкол 2003;1:107−16.5. Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74−6.Herr H.W. The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol 1999;162:74−6.6. Klan R., Loy V., Huland H. Residual tumor discovered in routine second TUR in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991;146:316.Klan R., Loy V., Huland H. Residual tumor discovered in routine second TUR in patients with stage T1 transitional cell carcinoma of the bladder. J Urol 1991;146:316.7. Herr H., Dalbagni G. Is second-look (re-staging) Transurethral resection of bladder tumors a new standard of care? Arab J Urol 2011;9:7−10.Herr H., Dalbagni G. Is second-look (re-staging) Transurethral resection of bladder tumors a new standard of care? Arab J Urol 2011;9:7−10.8. Ali M.H., Ismail I.Y., Eltobgy A., Gobeish A. Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cance r. J Endourol 2010;24(12):2047−50.Ali M.H., Ismail I.Y., Eltobgy A., Gobeish A. Evaluation of second-look transurethral resection in restaging of patients with nonmuscle-invasive bladder cance r. J Endourol 2010;24(12):2047−50.9. Dalbagni G., Vora K., Kaag M. et al. Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1. Blad Cancer 2009;56:903−10.Dalbagni G., Vora K., Kaag M. et al. Clinical Outcome in a Contemporary Series of Restaged Patients with Clinical T1. Blad Cancer 2009;56:903−10.10. Divrik R.T., Ali F.S., et al. Impact of Routine Second Transurethral Resection on the Long-Term Outcome of Patients with Newly Diagnosed pT1 Urothelial Carcinoma with Respect to Recurrence, Progression Rate, and Disease-Specific Survival: A Prospective Randomised Clinical Trial. Eur Urol 2010;5(8):185−90.Divrik R.T., Ali F.S., et al. Impact of Routine Second Transurethral Resection on the Long-Term Outcome of Patients with Newly Diagnosed pT1 Urothelial Carcinoma with Respect to Recurrence, Progression Rate, and Disease-Specific Survival: A Prospective Randomised Clinical Trial. Eur Urol 2010;5(8):185−90.11. Han K.S., Kyung Seok Han, Jae Young Joung et al. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer. J Endourol 2008;22(12):2699−704.Han K.S., Kyung Seok Han, Jae Young Joung et al. Results of repeated transurethral resection for a second opinion in patients referred for nonmuscle invasive bladder cancer. J Endourol 2008;22(12):2699−704.12. Schips L., Augustin H., Zigeuner R.E. et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59(2):220−3. http://www.ncbi.nlm.nih.gov/pubmed/11834389Schips L., Augustin H., Zigeuner R.E. et al. Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer? Urology 2002;59(2):220−3. http://www.ncbi.nlm.nih.gov/pubmed/1183438913. Schwaibold H.E., Sivalingam S., May F. et al. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006; 97:1199−201.Schwaibold H.E., Sivalingam S., May F. et al. The value of a second transurethral resection for T1 bladder cancer. BJU Int 2006; 97:1199−201.14. Cheng L., Montironi R., Davidson D., Lopez-Beltran A. Staging and reporting of urotelial carcinoma of the urinary bladder. Mod Pathol 2009;22:70−95.Cheng L., Montironi R., Davidson D., Lopez-Beltran A. Staging and reporting of urotelial carcinoma of the urinary bladder. Mod Pathol 2009;22:70−95.15. Zlotta A.R., van Vooren J.P., Huygen K. et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000; 37(4):470−7. http://www.ncbi.nlm.nih.gov/pubmed/10765079Zlotta A.R., van Vooren J.P., Huygen K. et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000; 37(4):470−7. http://www.ncbi.nlm.nih.gov/pubmed/1076507916. Herr H.W. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 2005;174:2134−7.Herr H.W. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy. J Urol 2005;174:2134−7.17. Stern M. Resections of obstructions at the vesical orifice. J Am Med Asso 1926; 87:1726−9.Stern M. Resections of obstructions at the vesical orifice. J Am Med Asso 1926; 87:1726−9.18. Herr H.W., Donat S.M., Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? Department of Urology, Memorial Sloan-Kettering Cancer Center, New York. NY, 2007.Herr H.W., Donat S.M., Dalbagni G. Can restaging transurethral resection of T1 bladder cancer select patients for immediate cystectomy? Department of Urology, Memorial Sloan-Kettering Cancer Center, New York. NY, 2007.19. Grimm M.O., Steinhoff Ch., Simon X. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170(2 Pt 1):433−7.Grimm M.O., Steinhoff Ch., Simon X. et al. Effect of routine repeat transurethral resection for superficial bladder cancer: a long-term observational study. J Urol 2003;170(2 Pt 1):433−7.20. Kulkarni G.S., Oliver W. Hakenberg, Juergen E. Gschwend et al. An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer Accepted 26 August 2009. Eur Urol 2010;57(1): 60−70.Kulkarni G.S., Oliver W. Hakenberg, Juergen E. Gschwend et al. An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer Accepted 26 August 2009. Eur Urol 2010;57(1): 60−70.